Metavia INC. (MTVA) — 8-K Filings

All 8-K filings from Metavia INC.. Browse 44 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (44)

8-K Filing — Apr 10, 2026
MetaVia Inc. Files 8-K on Financial Results — Mar 26, 2026
MetaVia Inc. filed an 8-K on March 26, 2026, reporting its results of operations and financial condition under Item 2.02. This filing indicates the company is r
8-K Filing — Dec 19, 2025
8-K Filing — Dec 2, 2025
8-K Filing — Nov 26, 2025
8-K Filing — Nov 7, 2025
MetaVia Inc. Files 8-K: Regulation FD & Financials — Aug 6, 2025 Risk: low
On August 6, 2025, MetaVia Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. MetaVia Inc.
MetaVia Inc. Files 8-K for Regulation FD and Financials — Aug 4, 2025 Risk: low
MetaVia Inc. filed an 8-K on August 4, 2025, to report information under Regulation FD and to file financial statements and exhibits. The company, formerly know
MetaVia Inc. Files 8-K with Regulatory Updates — Jul 9, 2025 Risk: low
MetaVia Inc. filed an 8-K on July 9, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as NeuroBo Ph
MetaVia Inc. Files 8-K on Security Holder Vote Matters — Jun 30, 2025 Risk: medium
On June 30, 2025, MetaVia Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as NeuroBo Pharm
MetaVia Inc. Faces Delisting Concerns — May 30, 2025 Risk: high
MetaVia Inc. filed an 8-K on May 30, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly kno
MetaVia Inc. Files 8-K, Former Names Revealed — May 21, 2025 Risk: low
On May 21, 2025, MetaVia Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 545 Concord Avenue, Suite 210,
MetaVia Inc. Files 8-K: Material Agreement, Equity Sales — May 14, 2025 Risk: medium
On May 8, 2025, MetaVia Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also reporte
MetaVia Inc. Files 8-K — May 7, 2025 Risk: low
MetaVia Inc. filed an 8-K on May 7, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as NeuroBo Pharmaceutical
MetaVia Inc. Files 8-K with Financials — Apr 22, 2025 Risk: low
On April 22, 2025, MetaVia Inc. filed an 8-K report. The filing primarily consists of financial statements and exhibits, with no specific material events or dis
MetaVia Inc. Files 8-K with Regulatory Updates — Apr 15, 2025 Risk: low
MetaVia Inc. filed an 8-K on April 15, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, an
MetaVia Inc. Files 8-K for Regulation FD Disclosure — Jan 10, 2025 Risk: low
On January 10, 2025, MetaVia Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and includes Financial Statem
MetaVia Inc. Files 8-K Report — Dec 18, 2024 Risk: low
On December 18, 2024, MetaVia Inc. filed an 8-K report. The filing primarily serves as a notification of the company's status and includes financial statements
MetaVia Inc. Files 8-K — Nov 29, 2024 Risk: low
MetaVia Inc. filed an 8-K on November 29, 2024, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as N
NeuroBo Pharmaceuticals Files 8-K with Corporate Updates — Nov 18, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on November 18, 2024, reporting events as of November 15, 2024. The filing indicates changes to its Articles of Incor
NeuroBo Pharmaceuticals Files 8-K — Nov 4, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on November 4, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerl
NeuroBo Pharmaceuticals Files 8-K — Oct 7, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on October 7, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not c
NeuroBo Pharmaceuticals Files 8-K — Sep 30, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on September 30, 2024, reporting on its financial statements and exhibits. The company, formerly known as Gemphire Th
NeuroBo Pharmaceuticals Files 8-K on Shareholder Vote Matters — Sep 19, 2024 Risk: medium
On September 18, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report to announce a submission of matters to a vote of its security holders. The filing does
NeuroBo Pharmaceuticals Files 8-K — Aug 13, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on August 13, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
NeuroBo Pharmaceuticals Files 8-K — Aug 6, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on August 6, 2024, to report on Regulation FD disclosures and financial statements. The company, formerly known as Ge
NeuroBo Pharmaceuticals Files 8-K — Jul 30, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on July 30, 2024, to report on Regulation FD disclosures and financial statements. The filing indicates the company's
NeuroBo Pharmaceuticals Files 8-K — Jul 16, 2024 Risk: low
On July 16, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine discl
NeuroBo Pharmaceuticals Files 8-K — Jun 26, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on June 26, 2024, to report other events and financial statements. The company, formerly known as Gemphire Therapeuti
NeuroBo Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Jun 25, 2024 Risk: medium
NeuroBo Pharmaceuticals, Inc. announced on June 23, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales
NeuroBo Pharmaceuticals Files 8-K — Jun 24, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on June 24, 2024, reporting other events and financial statements. The company, formerly known as Gemphire Therapeuti
NeuroBo Pharmaceuticals Appoints New Officers and Directors — Jun 7, 2024 Risk: medium
NeuroBo Pharmaceuticals, Inc. announced on June 7, 2024, the appointment of Dr. Sang-Jin Song as Chief Medical Officer and Dr. Jian Li as Chief Scientific Offic
NeuroBo Pharmaceuticals Files 8-K — May 22, 2024 Risk: low
On May 22, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
NeuroBo Pharmaceuticals Files 8-K — Apr 30, 2024 Risk: low
On April 30, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and includes financial state
NeuroBo Pharmaceuticals Files 8-K Report — Apr 17, 2024 Risk: low
On April 17, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material
NeuroBo Pharmaceuticals Files 8-K — Apr 16, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on April 16, 2024, reporting on other events and financial statements. The company, formerly Gemphire Therapeutics In
NeuroBo Pharmaceuticals Files 8-K — Apr 1, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on April 1, 2024, reporting other events and financial statements. The company, formerly known as Gemphire Therapeuti
NeuroBo Pharmaceuticals Files 8-K Report — Mar 13, 2024 Risk: low
On March 13, 2024, NeuroBo Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating ongoing operat
NeuroBo Pharmaceuticals Appoints New Director and CMO — Mar 4, 2024 Risk: medium
NeuroBo Pharmaceuticals, Inc. announced on March 4, 2024, the election of Dr. David Lee as a new director and the appointment of Dr. Jian Li as Chief Medical Of
NeuroBo Pharma Files 8-K on 'Other Events' and Financial Exhibits — Feb 29, 2024 Risk: low
NeuroBo Pharmaceuticals, Inc. filed an 8-K on February 29, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits'. The filing indicates a curren
NeuroBo Pharmaceuticals Files 8-K for 'Other Events' on Feb 14 — Feb 14, 2024 Risk: medium
NeuroBo Pharmaceuticals, Inc. filed an 8-K on February 14, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits.' The filing indicates the earl
NeuroBo Pharma Files Routine 8-K on Feb 1, No New Material Events — Feb 1, 2024
NeuroBo Pharmaceuticals, Inc. filed an 8-K on February 1, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates standard
NeuroBo Pharma Files Routine 8-K, Updates Corporate Info — Jan 18, 2024
NeuroBo Pharmaceuticals, Inc. filed an 8-K on January 18, 2024, to update its general corporate information, including its business address at 545 Concord Avenu
NeuroBo Pharma Files Routine 8-K on Jan 8 Event — Jan 9, 2024
NeuroBo Pharmaceuticals, Inc. filed an 8-K on January 9, 2024, reporting an event that occurred on January 8, 2024. This filing is a routine update to the SEC,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX